Shire claims a blockbuster in Vyvanse
This article was originally published in Scrip
Executive Summary
Shire can finally claim a blockbuster in Vyvanse (lisdexamfetamine), as it reported sales for its new ADHD treatment in 2012 of $1.03 billion, up 28% on the previous year. Further growth seems assured following EU approval in December. In addition, Phase III are trials ongoing with Vyvanse in major depressive disorder, binge eating disorder and negative symptoms of schizophrenia (scripintelligence.com, 16 January 2013). Total sales at Shire for 2012 were up 12% to $4.41 billion.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.